(Total Views: 637)
Posted On: 05/24/2020 1:34:42 PM
Post# of 155769
Translation:
On March 9, CytoDyn requested that the drug be tested for the treatment of patients with coronavirus, which was also given to them by the U.S. Pharmaceutical Authority under the Emergency Use Protocol. Data from nine previous and ongoing clinical trials have shown that leronlimab inhibits the migration of regulatory T cells to the site of inflammation, thereby reducing one of the most dangerous consequences of coronavirus infection, the cytokine storm induced by inflammatory cytokines. That is, in essence, the body can effectively regulate its own excessive immune response.
As of April 30, a total of 49 coronavirus patients had been treated with the product, so CytoDyn published the condition of the patients, which showed that the medicine was effective, especially in patients in crisis and in need of breathing. More than half of the artificially ventilated patients could be removed from the respirators.
Data from a further 10 patients have not yet been received and another 5 patients have been authorized for treatment with leronlimab, so that the effect of the study drug can be assessed based on the condition of at least 54 patients.
On March 9, CytoDyn requested that the drug be tested for the treatment of patients with coronavirus, which was also given to them by the U.S. Pharmaceutical Authority under the Emergency Use Protocol. Data from nine previous and ongoing clinical trials have shown that leronlimab inhibits the migration of regulatory T cells to the site of inflammation, thereby reducing one of the most dangerous consequences of coronavirus infection, the cytokine storm induced by inflammatory cytokines. That is, in essence, the body can effectively regulate its own excessive immune response.
As of April 30, a total of 49 coronavirus patients had been treated with the product, so CytoDyn published the condition of the patients, which showed that the medicine was effective, especially in patients in crisis and in need of breathing. More than half of the artificially ventilated patients could be removed from the respirators.
Data from a further 10 patients have not yet been received and another 5 patients have been authorized for treatment with leronlimab, so that the effect of the study drug can be assessed based on the condition of at least 54 patients.
(0)
(0)
